Antitrypsin Deficiency Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Antitrypsin Deficiency stocks.

Antitrypsin Deficiency Stocks Recent News

Date Stock Title
Nov 1 ALNY Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down
Nov 1 ALNY Alnylam Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Nov 1 ALNY Alnylam Pharmaceuticals Inc (ALNY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
Nov 1 ALNY Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight
Nov 1 ALNY Q3 2024 Alnylam Pharmaceuticals Inc Earnings Call
Oct 31 ALNY Alnylam Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Presentation
Oct 31 ALNY Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2024 Earnings Call Transcript
Oct 31 ALNY Alnylam (ALNY) Reports Q3 Earnings: What Key Metrics Have to Say
Oct 31 ALNY Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Lags Revenue Estimates
Oct 31 ALNY Alnylam: Q3 Earnings Snapshot
Oct 31 ALNY Alnylam Pharmaceuticals Non-GAAP EPS of -$0.50 misses by $0.11, revenue of $500.92M misses by $26.1M
Oct 31 ALNY Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity
Oct 31 NTLA Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024
Oct 31 NTLA Intellia Therapeutics (NTLA): Promising Gene Editing Stock with CRISPR-Cas9 Therapies
Oct 31 BEAM Beam Therapeutics (BEAM): Promising Gene Editing Stock with Base Editing Technology
Oct 30 ALNY Alnylam Pharmaceuticals Q3 2024 Earnings Preview
Oct 30 ALNY Cognizant signs deal to enhance Alnylam’s IT infrastructure
Oct 30 NTLA Reasons For Intellia Therapeutics Stock Plunge Are Flimsy, But Don't Buck Mr. Market
Oct 30 BEAM CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates
Oct 30 ALNY Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024
Antitrypsin Deficiency

Antitrypsin Deficiency is a genetic disorder that affects the lungs and liver. It is caused by a deficiency of the protein alpha-1 antitrypsin (AAT), which is produced in the liver and helps protect the lungs from damage. People with Antitrypsin Deficiency are at an increased risk of developing lung diseases such as emphysema and chronic obstructive pulmonary disease (COPD). They may also be at risk of developing liver disease. Treatment for Antitrypsin Deficiency includes lifestyle changes, medications, and in some cases, a liver transplant.

Browse All Tags